A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
Recruiting in Palo Alto (17 mi)
+7 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Metabolic Solutions Development Company
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Research Team
JR
Jerry R Colca, PhD
Principal Investigator
Metabolic Solutions Development Company
Eligibility Criteria
Inclusion Criteria
Diagnosis of Type 2 Diabetes naive or on metformin
Male and female (postmenopausal or surgically sterilized), 18 to 70 years of age.
Treatment Details
Interventions
- MSDC-0160 (Insulin Sensitizer)
- Pioglitazone (Insulin Sensitizer)
- Placebo (Drug)
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: MSDC-0160 90 mgExperimental Treatment1 Intervention
MSDC-0160 90 mg once daily
Group II: MSDC-0160 220 mgExperimental Treatment1 Intervention
MSDC-0160 220 mg once daily
Group III: PioglitazoneActive Control1 Intervention
Pioglitazone 45 mg once daily
Group IV: PlaceboPlacebo Group1 Intervention
Microcrystaline cellulose once daily
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metabolic Solutions Development Company
Lead Sponsor
Trials
4
Recruited
600+